Rheumatology Medical News about Biologics

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Use of Biologics for Psoriasis in Asia-Pacific Region
Current Rheumatology Reviews, 09/11/09

Tsai T–F et al. – Many controlled studies have been conducted to prove the safety and efficacy of biologics in the treatment of psoriasis. However, only limited data are available in Asia–Pacific region. Open label studies of efalizumab and alefacept have been conducted in Taiwan. This review article will detail on the published data in Asia–Pacific region of the six biologics indicated for the treatment of psoriasis, namely alefacept (Amevive), efalizumab (Raptiva), etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade) and ustekinumab (Stelara).

<< Previous
The reason for discontinuation of the first tumor necrosis factor...

Next >>
Early Diagnosis of AS or Other SpA - From Clinical and Radiologic...